The fate of chemoresistance in triple negative breast cancer (TNBC) - Test2 - elhamkhani - TriplyDB

The fate of chemoresistance in triple negative breast cancer (TNBC)

The fate of chemoresistance in triple negative breast cancer (TNBC)

http://www.wikidata.org/entity/Q26775232

about

Stimuli-Responsive Mesoporous Silica NPs as Non-viral Dual siRNA/Chemotherapy Carriers for Triple Negative Breast Cancer.Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas.Kaiso depletion attenuates the growth and survival of triple negative breast cancer cells miR-125b inhibited epithelial-mesenchymal transition of triple-negative breast cancer by targeting MAP2K7.Phototheranostics of CD44-positive cell populations in triple negative breast cancer.MiR-153 promotes breast cancer cell apoptosis by targeting HECTD3 Gold Nanoantenna-Mediated Photothermal Drug Delivery from Thermosensitive Liposomes in Breast Cancer.β1 Integrin as a Prognostic and Predictive Marker in Triple-Negative Breast Cancer Noscapine chemosensitization enhances docetaxel anticancer activity and nanocarrier uptake in triple negative breast cancer Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice.Understanding breast cancer - The long and winding road.Selective effects of non-thermal atmospheric plasma on triple-negative breast normal and carcinoma cells through different cell signaling pathways Triple negative breast cancer chemosensitivity and chemoresistance: current advances in biomarkers indentification.Garcinol sensitizes breast cancer cells to Taxol through the suppression of caspase-3/iPLA2 and NF-κB/Twist1 signaling pathways in a mouse 4T1 breast tumor model.Triple negative breast cancer: the kiss of death.Tackling breast cancer chemoresistance with nano-formulated siRNA.Epigenetic regulation of glycosylation and the impact on chemo-resistance in breast and ovarian cancer.Novel insight into triple-negative breast cancers, the emerging role of angiogenesis, and antiangiogenic therapy.Silencing the roadblocks to effective triple-negative breast cancer treatments by siRNA nanoparticles.T-independent response mediated by oncolytic tanapoxvirus recombinants expressing interleukin-2 and monocyte chemoattractant protein-1 suppresses human triple negative breast tumors.Peri-foci adipose-derived stem cells promote chemoresistance in breast cancer Potential Diagnostic and Therapeutic Applications of Oligonucleotide Aptamers in Breast Cancer STAT3 but Not HIF-1α Is Important in Mediating Hypoxia-Induced Chemoresistance in MDA-MB-231, a Triple Negative Breast Cancer Cell Line.APC loss in breast cancer leads to doxorubicin resistance via STAT3 activation.Flaxseed Lignans Enhance the Cytotoxicity of Chemotherapeutic Agents against Breast Cancer Cell Lines MDA-MB-231 and SKBR3.PP2A as the Main Node of Therapeutic Strategies and Resistance Reversal in Triple-Negative Breast Cancer.Bioimpedimetric analysis in conjunction with growth dynamics to differentiate aggressiveness of cancer cells.Hypoxia modulates the stem cell population and induces EMT in the MCF-10A breast epithelial cell line.Parthenolide prevents resistance of MDA-MB231 cells to doxorubicin and mitoxantrone: the role of Nrf2.MiR-539 inhibits proliferation and migration of triple-negative breast cancer cells by down-regulating LAMA4 expression.Cholecalciferol-PEG Conjugate Based Nanomicelles of Doxorubicin for Treatment of Triple-Negative Breast Cancer.BAG3 Overexpression and Cytoprotective Autophagy Mediate Apoptosis Resistance in Chemoresistant Breast Cancer Cells.Morphometric analysis of a triple negative breast cancer cell line in hydrogel and monolayer culture environments.MT4-MMP and EGFR expression levels are key biomarkers for breast cancer patient response to chemotherapy and erlotinib.Tumor xenograft modeling identifies an association between TCF4 loss and breast cancer chemoresistance.Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases.DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy

P2860

Q33635355-B5532E70-6CD7-4B98-9161-926AD64B5F90 Q36222283-6CC2C997-5CEB-4AD6-93B4-D3BFB449965D Q36319385-9BF8BB55-F40D-4BFC-A8DE-C2EBE590F1AE Q36891545-96854605-6C41-4955-8209-33D19AE2B799 Q37006182-7D4E20A9-426F-48E7-8058-CFF3BF962F4E Q37143959-8102295E-61BF-42EF-8553-1D92A4BD6B7C Q37262447-5E05110A-947D-4C6B-817B-147DEBA9D091 Q37286353-28CBEBB5-A5BE-4459-9D09-77767318A092 Q37426564-F40A4CCD-5141-42FB-BE2F-3B9A0D4DC90D Q37602839-3B8D1E8F-8AF2-469E-BFE2-401323C7908B Q37634220-A244BEAF-86DB-47C3-BDD5-79DD2B0727E5 Q38643585-FA08F477-2CAE-4FF1-B40A-3B8B87ED0686 Q38647802-D41072F5-6BB1-42AD-B5B3-9673002F1D8C Q38718506-CE8EDAD2-07B4-475C-BBCF-A02CCD7B51D4 Q38818744-6B443CBA-390C-4997-9C2B-FCCCBD204AD8 Q38959517-F4EE6DA7-B295-4E4B-8979-1A5B92F9604A Q38968841-81D866CF-08F7-40A0-B8CB-0BD774B1201A Q39000232-4EF1A991-B0D0-410E-8683-D26A6D1B04B6 Q39113994-E671C967-7381-424E-8550-D2E24E86B628 Q39499897-67CE7778-2F4B-4DB6-A4A8-0FD5215866D0 Q41163628-E754EA91-C7F7-4A8C-8DC1-4B1A172C12F8 Q41661268-ED1BE1BB-E81D-4DFC-B511-30C966ADE957 Q43499055-3FECE6E5-ECEB-4808-A970-5A89CD912FB0 Q47151712-2D6141AF-243C-477B-93E6-8CC4B81E5487 Q47206463-FB35F476-290D-48A7-87B0-E2B33596B6EE Q47271622-AABC697E-E960-4BB1-A404-DE702F7AB089 Q48042869-1BAB13F2-30C9-4B7E-A315-38EEB252F9F8 Q49183949-F2CACD2A-C319-45A8-9B6F-0BF309BEC1DF Q49193135-4710858D-F1E0-491B-92A4-3683A5F7B0AF Q49404188-5ED23591-CA70-4387-86AA-BA98A15261B5 Q49743645-16CB6B72-D69A-4CDF-BC86-07233A694998 Q49806879-69FE0487-DAD1-4EC2-A6C1-F02EDB8811EA Q50268380-E6A1C257-2E88-4327-81B4-F76DB41297FF Q50455931-674A61B1-456D-4554-90C1-AC1361B614B7 Q52318759-EAD461D8-C31D-475E-B6A9-8703CA3A2E16 Q54118354-43DF9474-40C8-46AA-8249-F1F24420B5C4 Q56889252-C0A7F56E-916B-4ABA-9308-8122D391515E

P2860

The fate of chemoresistance in triple negative breast cancer (TNBC)

http://www.wikidata.org/entity/Q26775232

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

The fate of chemoresistance in triple negative breast cancer (TNBC)

@ast

The fate of chemoresistance in triple negative breast cancer (TNBC)

@en

The fate of chemoresistance in triple negative breast cancer (TNBC)

@nl

type

label

The fate of chemoresistance in triple negative breast cancer (TNBC)

@ast

The fate of chemoresistance in triple negative breast cancer (TNBC)

@en

The fate of chemoresistance in triple negative breast cancer (TNBC)

@nl

prefLabel

The fate of chemoresistance in triple negative breast cancer (TNBC)

@ast

The fate of chemoresistance in triple negative breast cancer (TNBC)

@en

The fate of chemoresistance in triple negative breast cancer (TNBC)

@nl

P1433

Q26775232-29FEDFA9-E29C-4B49-BC13-EE70024ECB5D

P1476

Q26775232-DEDB57AE-6F72-4BB0-891A-8DD714A94BDF

P2093

Q26775232-1095ADC9-5270-4201-8AF5-10268586DF04

Q26775232-170DC1D4-04B9-4D93-99E5-67319AF17EA0

Q26775232-29042CE4-5EAB-4EB2-AB6B-A0E31C041EFF

Q26775232-54FE88AF-C028-4120-BADB-CA662149A896

Q26775232-56925DAF-E7A5-4DAC-BDF5-5D3A393822A8

Q26775232-B99A2DD4-4230-4DDE-A4A3-837B0393BD54

Q26775232-CF788F99-5C2C-43E0-9AE4-8EB9CF73713A

Q26775232-EC4313C9-4003-4305-B47D-0B10C7CE2941

P2860

Q26775232-00A88CD1-BD94-49B8-9723-6C71E0780BE4

Q26775232-00B93864-56B0-4DD4-A748-5F1279459A33

Q26775232-04534B5C-E9A8-4E40-8BEA-23C25C706073

Q26775232-046BA457-9DDE-4382-8096-1BEEFE3C6E3F

Q26775232-06A6F820-D18F-46AF-B529-E816D5EF46AF

Q26775232-07835BF7-FC9B-43E7-8333-AA1424DF6B60

Q26775232-07ED1B6D-AE0D-45F0-ABDE-6728F2DCF548

Q26775232-07EF295E-1EC2-40C8-98D1-AB21F48ADD31

Q26775232-08CD5192-3806-45B0-B43C-48572F703A9C

Q26775232-09CDE167-A720-42A6-B6B3-D5091CE925A3

P304

Q26775232-2306A1D4-12D7-48BB-8F47-E87DCB27C9CB

P31

Q26775232-B6548717-BF40-407A-AEF8-7A438B8BE1B8

P3181

Q26775232-89A78B9E-146E-4F34-A957-31AAC2B180ED

P356

Q26775232-35A2F1D8-F133-4220-8A91-D58BAA29A583

P407

Q26775232-291DAC4D-D504-402B-82F6-8A0B7DDD04BD

P478

Q26775232-161D7F03-BB2F-4A59-94DB-1812E66FAC18

P50

Q26775232-48765FAC-91AB-47C8-8FA4-DF198F5B2DCC

Q26775232-5C6E6F60-2D8C-4852-9459-85D5F086FD6F

Q26775232-97581199-E7BB-4883-90C7-DBFDB080D082

P577

Q26775232-D1770140-8598-4737-8169-2EDCFEA5B2F8

P5875

Q26775232-0CC7A2D6-5416-4045-852C-5DF4F4F219BE

P698

Q26775232-5B1DE9A2-33F8-434C-9C98-6AE4CC6C9BBA

P932

Q26775232-9D15CD9D-B23B-4E7A-83AC-DC1F8EA636CA

P3181

P356

J.BBACLI.2015.03.003

P1433

P1476

The fate of chemoresistance in triple negative breast cancer (TNBC)

@en

P2093

Elma A O'Reilly

http://www.w3.org/2001/XMLSchema#string

John McCaffrey

http://www.w3.org/2001/XMLSchema#string

Karolina Weiner-Gorzel

http://www.w3.org/2001/XMLSchema#string

Malcolm Kell

http://www.w3.org/2001/XMLSchema#string

Matthew Ho Zhing Guang

http://www.w3.org/2001/XMLSchema#string

Michele Harrison

http://www.w3.org/2001/XMLSchema#string

Riona Tully

http://www.w3.org/2001/XMLSchema#string

Shiva Sharma

http://www.w3.org/2001/XMLSchema#string

P2860

Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase

KIF14 promotes AKT phosphorylation and contributes to chemoresistance in triple-negative breast cancer

Understanding and treating triple-negative breast cancer

The epithelial-mesenchymal transition generates cells with properties of stem cells

Targeting the mTOR signaling network for cancer therapy

Targeting triple-negative breast cancer: optimising therapeutic outcomes

Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment

Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

P304

257-275

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

752165

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.BBACLI.2015.03.003

http://www.w3.org/2001/XMLSchema#string

P407

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-03-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273524404

http://www.w3.org/2001/XMLSchema#string

P698

26676166

http://www.w3.org/2001/XMLSchema#string

P932

4661576

http://www.w3.org/2001/XMLSchema#string